If you have been tracking admp stock (Adamis Pharmaceuticals Corporation) over the past several years, you have witnessed one of the most turbulent, complex, and cautionary tales in the modern microcap biotech sector. Once heralded as a highly promising challenger to pharmaceutical giants with its innovative drug-delivery systems, the company ultimately succumbed to a combination of commercial failures, value-destructive mergers, regulatory actions, and severe corporate fraud.
As of 2026, the company formerly known as Adamis Pharmaceuticals has ceased to exist as an active business. Following a series of highly dilutive reverse stock splits, a merger with DMK Pharmaceuticals, a Chapter 11 bankruptcy filing, and a major SEC enforcement action that culminated in early 2025, the stock—which last traded under the OTC ticker symbol DMKPQ—has been completely liquidated, and its remaining shares have been canceled.
In this definitive guide, we will unpack the complete timeline of ADMP stock. We will examine the initial promise of its lead products, the strategic pivot that briefly offered a glimmer of hope, the illegal kickback scheme that triggered its downfall, and the final liquidating plan. Finally, we will outline the crucial lessons that every retail investor can learn from this biotech tragedy to protect their capital in the volatile microcap markets.
The History and Promise of Adamis Pharmaceuticals (ADMP)
To understand how ADMP stock collapsed, it is essential to look back at the company's early potential and the massive market opportunities it targeted. Founded as a specialty biopharmaceutical company based in San Diego, California, Adamis Pharmaceuticals focused on developing and commercializing products in high-demand therapeutic areas, including severe allergies, respiratory diseases, and opioid overdoses.
The Challenger to the EpiPen: Symjepi
For years, the crown jewel of the Adamis pipeline was Symjepi (epinephrine injection). Symjepi was designed as a low-cost, pre-filled syringe alternative to Viatris's (formerly Mylan's) EpiPen.
The context surrounding Symjepi’s development is vital. In 2016, Mylan faced intense public outrage, media scrutiny, and congressional hearings after raising the price of a two-pack of EpiPens to over $600. This created a massive public demand for affordable epinephrine alternatives.
Symjepi presented a perfect solution. Instead of a bulky, complex auto-injector, Symjepi utilized a pre-filled, single-dose syringe that was smaller, more portable, and cheaper to manufacture. The FDA approved Symjepi (0.3mg) for adults in 2017 and a pediatric version (0.15mg) in 2018. Investors rushed into ADMP stock, believing the company was positioned to capture a massive slice of the multi-billion-dollar emergency epinephrine market.
However, the pre-filled syringe design carried a subtle commercial disadvantage. Unlike the EpiPen, which features a spring-loaded, hidden needle that deploys automatically when pressed against the thigh, Symjepi required the user to manually insert the needle and push a plunger. In highly stressful, life-or-death anaphylaxis situations, many doctors and patients preferred the automated simplicity of the EpiPen, limiting Symjepi's clinical adoption.
Addressing the Opioid Crisis: Zimhi
Seeking to replicate its pre-filled syringe success, Adamis developed Zimhi (naloxone hydrochloride injection), a high-dose (5mg/0.5mL) pre-filled syringe designed for the rapid reversal of opioid overdoses.
With the synthetic opioid crisis and fentanyl overdoses ravaging the United States, there was an urgent public health need for higher-dose naloxone products. Zimhi received fast-track attention and secured FDA approval in late 2021.
With two FDA-approved commercial products addressing massive public health markets, Adamis appeared to have won the biotech lottery. Yet, the gap between regulatory approval and commercial success proved to be an insurmountable chasm.
The Commercialization Chasm
Adamis lacked the capital, sales force, and distribution infrastructure to market Symjepi and Zimhi on its own. To overcome this, the company relied on licensing and distribution agreements. Initially, they partnered with Sandoz, a division of Novartis, to commercialize Symjepi. However, Sandoz struggled to secure significant market penetration against entrenched competitors, and the agreement was eventually terminated.
Adamis then turned to US WorldMeds (USWM) as its exclusive commercialization partner for both Symjepi and Zimhi. Despite marketing campaigns and distribution rollouts, commercial traction remained sluggish. The company was burning through cash at an unsustainable rate to maintain operations, fund manufacturing, and service its debt.
To survive, the company repeatedly turned to the capital markets, executing highly dilutive public offerings of common stock and reverse stock splits. By late 2022, CEO David J. Marguglio announced that the board had hired an investment bank to explore "strategic alternatives," including a sale of the company, a merger, or licensing out its remaining assets.
The Strategic Pivot: The DMK Merger and Name Change
In May 2023, Adamis Pharmaceuticals announced the closing of an all-stock merger with DMK Pharmaceuticals Corporation, a privately held, clinical-stage neuro-biotechnology company. The transaction was framed as a transformational pivot that would salvage the company’s commercial assets while introducing a high-upside drug development pipeline.
The Leadership and Pipeline Shift
Following the merger, DMK’s CEO, Ebrahim "Eboo" Versi, MD, PhD, was named CEO and Chairman of the combined public company. DMK brought a proprietary library of small-molecule development candidates designed to treat neurological and substance use disorders.
The lead development program in the combined pipeline was DPI-125, a clinical-stage therapeutic under investigation for the treatment of opioid use disorder (OUD). DPI-125 was designed as a dual-acting delta/mu opioid receptor modulator, aiming to mitigate withdrawal symptoms and cravings without the addictive and respiratory-depressive risks associated with traditional treatments like methadone or buprenorphine.
The strategic logic of the merger was to use the potential future cash flows from Symjepi and Zimhi to fund the clinical development of DPI-125 and other neurological candidates, creating a diversified, clinical-stage biopharmaceutical leader.
Rebranding to DMK Pharmaceuticals
To reflect this new strategic focus, the company officially changed its name from Adamis Pharmaceuticals Corporation to DMK Pharmaceuticals Corporation. On September 7, 2023, the common stock transitioned away from its historic ticker, ADMP stock, and began trading on the Nasdaq Capital Market under the ticker symbol DMK.
For retail investors who had held ADMP stock through years of decline, the merger offered a brief moment of hope. However, the corporate marriage did little to resolve the underlying cash crisis. The combined company's balance sheet remained severely distressed, and the clinical trials for DPI-125 required millions of dollars in capital that the company simply did not possess.
By November 2023, the commercial situation had deteriorated further. DMK announced that it was reacquiring the full distribution and commercialization rights for Symjepi and Zimhi back from US WorldMeds, seeking to out-license the products to other global partners to generate immediate non-dilutive upfront cash. This desperate search for cash was a clear warning sign that the company was running out of time.
The Downward Spiral: SEC Fraud Charges, Criminal Fines, and Bankruptcies
While the executive team tried to rescue the company’s finances through the DMK merger, a historical corporate scandal from the Adamis era was quietly catching up with them. This scandal would ultimately destroy any remaining viability the business had.
The US Compounding Fraud Scheme
The root of this systemic failure dates back to April 2016, when Adamis acquired US Compounding Inc. (USC), a registered drug compounding outsourcing facility based in Conway, Arkansas. USC was acquired to provide immediate, diversified revenue to support Adamis’s primary drug development pipeline. Under Section 503B of the Food, Drug, and Cosmetic Act, outsourcing facilities are permitted to compound sterile drugs in bulk without patient-specific prescriptions, provided they comply with strict Current Good Manufacturing Practices (CGMP).
Instead of a steady revenue stream, US Compounding became a hotbed of illegal activity. According to investigations by the Department of Justice (DOJ) and the Securities and Exchange Commission (SEC), US Compounding engaged in a massive drug kickback and prescription fraud scheme from 2016 until the facility was finally shut down in October 2021.
The fraudulent scheme involved paying illegal commissions to salespeople and a veterinarian to generate prescriptions for compounded animal medications. To bypass federal anti-kickback laws and veterinary pharmacy regulations, the veterinarian was paid monthly fees under a sham "consulting agreement" that was actually a direct 10% commission on the compounding revenue generated by his illegal prescriptions.
These illicit veterinary sales made up a material percentage of US Compounding's revenues, which were subsequently consolidated into Adamis’s public financial reports. Robert O. Hopkins, who served as the Vice President of Finance, Chief Financial Officer, and Secretary of Adamis from 2009 until August 2021, was central to the cover-up. Hopkins falsified internal bookkeeping records, signed false SEC filings, and deceived the company's external auditors to hide the fraudulent kickback scheme.
The Legal and Criminal Reckoning
The legal fallout from the US Compounding scheme was catastrophic:
- Criminal Convictions: In July 2025, Sam Glover, a former executive at U.S. Compounding, was convicted in federal court of conspiracy, drug adulteration, and misbranding under the Federal Food, Drug, and Cosmetic Act. Prosecutors demonstrated that the adulterated drugs were distributed without valid prescriptions, putting animal health at risk and defrauding the market.
- Corporate Plea Agreement: DMK (as the successor to Adamis) entered into a criminal plea agreement with the U.S. government, resulting in a $4.2 million forfeiture payment and a criminal fine of up to $16.9 million.
- SEC Sanctions (January 2025): The SEC issued a formal Cease-and-Desist Order against DMK Pharmaceuticals and Robert O. Hopkins. The SEC order required the payment of $334,314 in disgorgement and prejudgment interest. Hopkins was permanently barred from serving as an officer or director of a publicly traded company and was banned from practicing as an accountant before the SEC.
The Chapter 11 Bankruptcy Filing
Faced with millions of dollars in criminal fines, mounting legal defense costs, a total lack of operating capital, and delisting threats from the Nasdaq, DMK Pharmaceuticals and its wholly-owned subsidiaries (including Adamis Pharmaceuticals, Biosyn, Rhombus Pharmaceuticals, and US Compounding) filed for Chapter 11 bankruptcy protection on February 2, 2024, in the U.S. Bankruptcy Court for the District of Delaware.
Upon filing, the Nasdaq halted trading of DMK stock. The company was officially delisted from the exchange, and its shares were relegated to the over-the-counter (OTC) Pink Sheets under the ticker symbol DMKPQ. The addition of the "Q" suffix served as a universal warning to the market that the issuer was in active bankruptcy proceedings.
The Current Status of ADMP/DMK Stock (DMKPQ)
If you are a retail investor holding legacy shares of ADMP stock, or if you purchased DMK / DMKPQ shares during the bankruptcy slide, it is crucial to understand the finality of the liquidation process.
The Structured Liquidation of Assets
Under the supervision of the Delaware Bankruptcy Court (Jointly Administered Case No. 1:24-bk-10153), DMK Pharmaceuticals did not attempt to restructure and emerge as an active business. Instead, the company executed a structured liquidation of its remaining intellectual property and commercial rights:
- The Zimhi Asset Sale: In May 2024, the court approved the sale of all assets related to the Zimhi products and business to ZMI Pharma Inc. for $3,170,600.
- Executive and Board Exodus: On June 27, 2024, CEO Ebrahim Versi, along with board members Howard C. Birndorf, Meera J. Desai, Vickie S. Reed, and Jannine C. A. Versi, resigned from the company. CFO Seth Cohen was appointed as the Chief Restructuring Officer to manage the remaining wind-down.
- The Liquidation Trust: The court approved the First Amended Joint Plan of Liquidation, which transferred all remaining property, legal claims, and residual assets of the debtors to the DMK Liquidation Trust, managed by RK Consultants, LLC as the Liquidation Trustee.
The Absolute Priority Rule and Equity Cancellation
In a corporate liquidation, the distribution of proceeds is governed strictly by the Absolute Priority Rule under the U.S. Bankruptcy Code. The recovery waterfall is structured as follows:
- Administrative Expenses: Court costs, legal fees, and the expenses of the liquidation trustee (RK Consultants, LLC) are paid first.
- Secured Creditors: Lenders with collateralized debt.
- Priority Unsecured Claims: Employee wages and government tax claims.
- General Unsecured Creditors: Suppliers, contract manufacturers (such as Catalent Belgium, which filed a disputed €1.5 million claim), and trade partners.
- Preferred Shareholders
- Common Shareholders (Retail Investors)
Because the total proceeds from the asset sales (such as the $3.17 million from Zimhi) were far lower than the outstanding debts, criminal fines, and administrative expenses of the bankruptcy estate, there was absolutely no capital remaining for equity holders.
By early 2026, the liquidation trustee completed the distribution of the minimal remaining cash to the high-priority creditors. In accordance with the court-approved liquidation plan, all outstanding shares of DMKPQ (formerly ADMP and DMK) were officially canceled and deemed worthless. An SEC Form 25 was filed around March 2, 2026, finalizing the delisting and removing the ticker symbol from all public trading systems. The shares have no remaining value, do not represent ownership in any active business, and can no longer be traded.
Key Takeaways and Lessons for Biotech & Microcap Investors
The multi-year destruction of shareholder value in ADMP stock serves as a powerful cautionary tale of the structural hazards inherent in microcap biotech investing. While the potential for triple-digit spikes often lures retail traders to penny stocks, the structural risks are severe. Here are the core lessons to draw from the demise of Adamis Pharmaceuticals:
1. FDA Approval is Not a Commercial Guarantee
A common misconception among retail biotech investors is that FDA approval is the final hurdle to profitability. ADMP proved that obtaining regulatory clearance is merely the end of the beginning. An approved drug is a commercial failure if a small company lacks the capital to build a dedicated sales force, secure favorable formulary placement with insurance companies, or compete with established pharmaceutical giants.
When evaluating clinical-stage biotechs, look closely at their commercial launch strategies, the terms of their distribution agreements, and the competitive landscape. If a company relies on third-party commercializers who have multiple competing priorities, the drug is likely to languish.
2. The Danger of the "Dilution Spiral"
Biotech development and drug commercialization are incredibly capital-intensive. Adamis and DMK consistently burned millions of dollars of cash per quarter while generating negligible revenues. To survive, they relied on dilutive financing, issuing millions of new shares of common stock, often accompanied by warrants.
To maintain compliance with the Nasdaq’s minimum bid price rule ($1.00), the company had to execute reverse stock splits. While reverse stock splits artificially boost the share price, they drastically reduce the share count of existing retail holders. This is a classic "dilution spiral" that systematically destroys long-term shareholder value. Always monitor a company’s cash runway (cash on hand divided by quarterly cash burn) and avoid companies that rely heavily on serial stock dilution to fund basic operations.
3. Corporate Governance and Subsidiary Oversight
The illegal kickback scheme at US Compounding highlights how weak internal controls and poor corporate governance can destroy a public company. Adamis acquired US Compounding to diversify its revenue, but the lack of oversight allowed fraudulent activity to corrupt the company's financial statements.
Investors must perform rigorous due diligence on a company's leadership and corporate structure. Frequent delays in filing quarterly or annual reports, abrupt changes in external auditing firms, and regulatory warnings (such as FDA Form 483s or warning letters sent to subsidiaries) are major red flags that should prompt investors to exit a position immediately.
4. Bankruptcy is a Terminal Event for Common Equity
Many retail investors fall into the trap of "buying the dip" on a distressed stock that has dropped 95%, or worse, buying shares of a company that has already filed for Chapter 11 bankruptcy (relegated to the OTC market with a "Q" suffix). This speculative behavior is fueled by rare, outlier cases where bankrupt companies (like Hertz) managed to restructure and provide a recovery for common shareholders.
The reality is that the vast majority of Chapter 11 cases end in total liquidation or restructuring plans where existing common equity is completely wiped out and replaced with new shares issued to creditors. Speculating on a "Q" stock is a statistically losing bet. Once a company enters Chapter 11 with severe debt and low asset valuations, the safest course of action is to sell the stock and claim a capital loss.
Frequently Asked Questions (FAQs)
What happened to ADMP stock?
ADMP stock (Adamis Pharmaceuticals) merged with DMK Pharmaceuticals in May 2023. Following the merger, the company changed its name to DMK Pharmaceuticals Corporation and its Nasdaq ticker symbol to DMK. Due to high debts, legal liabilities, and lack of capital, the company filed for Chapter 11 bankruptcy in February 2024, and its stock was officially canceled and delisted in early 2026.
Is Adamis / DMK Pharmaceuticals still trading?
No. All common shares of the company (formerly trading under the symbols ADMP, DMK, and DMKPQ) have been officially canceled under a court-approved Chapter 11 liquidation plan. An SEC Form 25 was filed in March 2026 to finalize the delisting. The stock is completely inactive and can no longer be bought, sold, or traded on any public or OTC exchange.
What does the "Q" in DMKPQ stand for?
The letter "Q" added to the end of a stock ticker symbol (such as DMK becoming DMKPQ) is a standard identifier used by OTC Markets and major exchanges to indicate that the issuing company has filed for bankruptcy protection under the U.S. Bankruptcy Code.
Who owns the rights to Symjepi and Zimhi now?
In mid-2024, the bankruptcy court approved the sale of the company's Zimhi-related commercial assets and intellectual property to ZMI Pharma Inc. for approximately $3.17 million. The remaining assets of Adamis and DMK were transferred to a liquidating trust managed by RK Consultants, LLC for the benefit of high-priority creditors.
How can I claim a tax write-off for my worthless ADMP/DMKPQ shares?
Because your shares have been officially canceled and deemed worthless, you can generally claim a capital loss on your federal income tax return. You will need to obtain a year-end tax document or confirmation of worthlessness from your stock brokerage. You can use this to report a capital loss on IRS Form 8949 and Schedule D. It is highly recommended to consult with a certified public accountant (CPA) or tax professional to ensure the loss is filed correctly according to your local tax laws.
Conclusion
The multi-year saga of admp stock serves as a powerful cautionary tale of the structural hazards inherent in microcap biotech investing. The transition of Adamis Pharmaceuticals from a promising developer of emergency medical devices to a liquidated, bankrupt estate underscores the cold reality of the financial market: a drug cannot succeed on therapeutic merit alone; it requires operational competence, financial discipline, commercial scale, and unwavering corporate integrity.
While legacy shareholders have been completely wiped out through the final cancellation of DMKPQ shares in 2026, the structural lessons of the Adamis and DMK collapse remain vital tools for any investor looking to successfully navigate the high-risk, high-reward landscape of biopharmaceutical stocks.
